Abstract
Orally bioavailable, dual inhibitors of TIE-2/VEGF-R2 were identified by elaborating the C3/N13 SAR around a fused pyrrolodihydroindazolocarbazole scaffold. Analogs bearing a C3-thiophencarbonyl group were evaluated in enzymatic and cellular biochemical assays; two orally bioavailable analogs were further profiled in functional assays and found to inhibit microvessel growth in rat aortic explant cultures and inhibit Ang-1-stimulated chemotaxis of HUVECs.
MeSH terms
-
Acylation
-
Angiogenesis Inhibitors / chemical synthesis
-
Angiogenesis Inhibitors / pharmacokinetics*
-
Angiotensin I
-
Animals
-
Aorta / cytology
-
Aorta / drug effects*
-
Aorta / metabolism
-
Biological Availability
-
Cells, Cultured
-
Chemotaxis / physiology
-
Endothelial Cells / cytology
-
Endothelial Cells / drug effects*
-
Endothelial Cells / metabolism
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / pharmacokinetics*
-
Indazoles / chemical synthesis
-
Indazoles / pharmacology*
-
Indoles / chemical synthesis
-
Indoles / pharmacology*
-
Models, Chemical
-
Rats
-
Receptor, TIE-2 / antagonists & inhibitors*
-
Structure-Activity Relationship
-
Thiophenes / chemistry
-
Umbilical Veins / cytology
-
Umbilical Veins / drug effects*
-
Umbilical Veins / metabolism
-
Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors*
Substances
-
Angiogenesis Inhibitors
-
Enzyme Inhibitors
-
Indazoles
-
Indoles
-
Thiophenes
-
Angiotensin I
-
Receptor, TIE-2
-
Vascular Endothelial Growth Factor Receptor-2